173 related articles for article (PubMed ID: 36516442)
1. The Identification of Potent, Selective, and Brain Penetrant PI5P4Kγ Inhibitors as In Vivo-Ready Tool Molecules.
Rooney TPC; Aldred GG; Boffey HK; Willems HMG; Edwards S; Chawner SJ; Scott DE; Green C; Winpenny D; Skidmore J; Clarke JH; Andrews SP
J Med Chem; 2023 Jan; 66(1):804-821. PubMed ID: 36516442
[TBL] [Abstract][Full Text] [Related]
2. Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.
Boffey HK; Rooney TPC; Willems HMG; Edwards S; Green C; Howard T; Ogg D; Romero T; Scott DE; Winpenny D; Duce J; Skidmore J; Clarke JH; Andrews SP
J Med Chem; 2022 Feb; 65(4):3359-3370. PubMed ID: 35148092
[TBL] [Abstract][Full Text] [Related]
3. Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.
Willems HMG; Edwards S; Boffey HK; Chawner SJ; Green C; Romero T; Winpenny D; Skidmore J; Clarke JH; Andrews SP
RSC Med Chem; 2023 May; 14(5):934-946. PubMed ID: 37252102
[TBL] [Abstract][Full Text] [Related]
4. Development of potent and selective degraders of PI5P4Kγ.
Ji W; Wang ES; Manz TD; Jiang J; Donovan KA; Abulaiti X; Fischer ES; Cantley LC; Zhang T; Gray NS
Eur J Med Chem; 2023 Feb; 247():115027. PubMed ID: 36584631
[TBL] [Abstract][Full Text] [Related]
5. The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K).
Aldred GG; Rooney TPC; Willems HMG; Boffey HK; Green C; Winpenny D; Skidmore J; Clarke JH; Andrews SP
RSC Med Chem; 2023 Oct; 14(10):2035-2047. PubMed ID: 37859710
[TBL] [Abstract][Full Text] [Related]
6. The function of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) explored using a specific inhibitor that targets the PI5P-binding site.
Clarke JH; Giudici ML; Burke JE; Williams RL; Maloney DJ; Marugan J; Irvine RF
Biochem J; 2015 Mar; 466(2):359-67. PubMed ID: 25495341
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity.
Němec V; Khirsariya P; Janovská P; Moyano PM; Maier L; Procházková P; Kebková P; Gybel' T; Berger BT; Chaikuad A; Reinecke M; Kuster B; Knapp S; Bryja V; Paruch K
Angew Chem Int Ed Engl; 2023 Mar; 62(11):e202217532. PubMed ID: 36625768
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ), a lipid signalling enigma.
Giudici ML; Clarke JH; Irvine RF
Adv Biol Regul; 2016 May; 61():47-50. PubMed ID: 26710750
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Structure-Activity Relationship Study of (
Manz TD; Sivakumaren SC; Ferguson FM; Zhang T; Yasgar A; Seo HS; Ficarro SB; Card JD; Shim H; Miduturu CV; Simeonov A; Shen M; Marto JA; Dhe-Paganon S; Hall MD; Cantley LC; Gray NS
J Med Chem; 2020 May; 63(9):4880-4895. PubMed ID: 32298120
[TBL] [Abstract][Full Text] [Related]
10. Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.
Lovering F; Morgan P; Allais C; Aulabaugh A; Brodfuehrer J; Chang J; Coe J; Ding W; Dowty H; Fleming M; Frisbie R; Guzova J; Hepworth D; Jasti J; Kortum S; Kurumbail R; Mohan S; Papaioannou N; Strohbach JW; Vincent F; Lee K; Zapf CW
Eur J Med Chem; 2018 Feb; 145():606-621. PubMed ID: 29348070
[TBL] [Abstract][Full Text] [Related]
11. Identification of highly potent and selective PI3Kδ inhibitors.
Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
[TBL] [Abstract][Full Text] [Related]
12. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1
Candito DA; Simov V; Gulati A; Kattar S; Chau RW; Lapointe BT; Methot JL; DeMong DE; Graham TH; Kurukulasuriya R; Keylor MH; Tong L; Morriello GJ; Acton JJ; Pio B; Liu W; Scott JD; Ardolino MJ; Martinot TA; Maddess ML; Yan X; Gunaydin H; Palte RL; McMinn SE; Nogle L; Yu H; Minnihan EC; Lesburg CA; Liu P; Su J; Hegde LG; Moy LY; Woodhouse JD; Faltus R; Xiong T; Ciaccio P; Piesvaux JA; Otte KM; Kennedy ME; Bennett DJ; DiMauro EF; Fell MJ; Neelamkavil S; Wood HB; Fuller PH; Ellis JM
J Med Chem; 2022 Dec; 65(24):16801-16817. PubMed ID: 36475697
[TBL] [Abstract][Full Text] [Related]
14. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
15. Identification of death-associated protein kinases inhibitors using structure-based virtual screening.
Okamoto M; Takayama K; Shimizu T; Ishida K; Takahashi O; Furuya T
J Med Chem; 2009 Nov; 52(22):7323-7. PubMed ID: 19877644
[TBL] [Abstract][Full Text] [Related]
16. Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.
Safina BS; Sweeney ZK; Li J; Chan BK; Bisconte A; Carrera D; Castanedo G; Flagella M; Heald R; Lewis C; Murray JM; Nonomiya J; Pang J; Price S; Reif K; Salphati L; Seward EM; Wei B; Sutherlin DP
Bioorg Med Chem Lett; 2013 Sep; 23(17):4953-9. PubMed ID: 23867164
[TBL] [Abstract][Full Text] [Related]
17. Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
Liu K; Zheng W; Chen Y; Tang M; Li D; Deng D; Yang T; Zhang C; Liu J; Yuan X; Shi M; Li X; Guo Y; Zhou Y; Zhao M; Chen L
J Med Chem; 2022 Jul; 65(14):9893-9917. PubMed ID: 35831917
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer.
Akhtar N; Jabeen I
Curr Cancer Drug Targets; 2018; 18(9):830-846. PubMed ID: 28669343
[TBL] [Abstract][Full Text] [Related]
19. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
20. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
Hua Z; Huang X; Bregman H; Chakka N; DiMauro EF; Doherty EM; Goldstein J; Gunaydin H; Huang H; Mercede S; Newcomb J; Patel VF; Turci SM; Yan J; Wilson C; Martin MW
Bioorg Med Chem Lett; 2012 Sep; 22(17):5392-5. PubMed ID: 22877629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
